News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Vetter Pharma-Fertigung GmbH & Co. KG Launches New Subsidiary


3/18/2009 8:20:03 AM

RAVENSBURG, Germany--(BUSINESS WIRE)--Vetter Pharma-Fertigung GmbH & Co. KG (VPF) today announced the formation of a new subsidiary, Vetter Pharma International GmbH (VPI). With a scheduled launch date of April 1, 2009, VPI will be responsible for all Vetter sales, marketing and customer service activities on a worldwide level.

Peter Soelkner has been named Managing Director, and Oskar Gold will serve as Vice President of the new entity. Headquarters will be in Ravensburg, Germany, and Vetter Pharma International USA Inc. will be located in Yardley, PA.

“The formation of VPI allows us to better position ourselves as a worldwide leader in pre-filled aseptic injection solutions,” Soelkner said. “By creating an entity that focuses exclusively on sales, marketing and customer service on a global level, Vetter will move significantly closer to the international market and can build even stronger relationships with our clients and prospects throughout the world.”

VPF, which previously has managed all of Vetter’s sales, services and manufacturing activities under a single corporate umbrella, will now focus exclusively on the company’s manufacturing and pharmaceutical operations. "VPF will continue to be a strong partner for pharmaceutical and biotech companies, providing high quality pharmaceutical services that support the supply chain of aseptically pre-filled injectable products, from clinical development to market launch to ongoing delivery worldwide," said Soelkner.

“By realigning our resources to empower each entity’s core competencies, both VPI and VPF alike can be major catalysts in Vetter’s continued growth and expansion in the years to come—no matter how much the industry may change,” he added.

Background:

About Vetter Pharma-Fertigung GmbH & Co. KG: Vetter is an independent international specialist in the aseptic filling of syringes, cartridges and vials. Based in Ravensburg, Germany, Vetter also produces its own injection systems, such as the Vetter Lyo-Ject® dual-chamber syringe. With about 1,900 employees worldwide, Vetter holds nearly 140 patents and has longstanding experience in handling client products and processes approved by the FDA, the EMEA and other authorities. In 2007, the company also received the go-ahead as a foreign manufacturer for the Japanese pharmaceutical market from Japan’s Ministry for Health, Labor and Welfare. Additionally, Vetter has received two awards for its new facility Ravensburg Vetter South (RVS): The Facility of the Year Award 2007 (Process Innovation category) and the European Outsourcing Award 2007 (Most Improved Process/Plant/Facility category).

Vetter Development Service provides support for its pharmaceutical and biotech clients in the early stages of development, from clinical phases and regulatory approval to worldwide product launch. Vetter Commercial Manufacturing handles the entire production process, from compounding and aseptic filling to the final packaging of a product. Vetter Solutions’ patented application systems enable clients to compete more effectively throughout the world.

Contact:

Vetter Pharma-Fertigung GmbH & Co. KG Oskar Gold, +49-(0)751-3700 - 0 Fax: +49-(0)751-3700 - 40 00 E-mail: info@vetter-pharma.com www.vetter-pharma.com


Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES